Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- A study presented at the World Ophthalmology Congress in Prague examined whether newer dry AMD treatments increase the treatment burden for patients concurrently receiving therapy for wet AMD. - Researchers found that adding newer dry age-related macular degeneration therapies did not appear to increase the treatment burden for the wet form of the disease. - The findings address a critical knowledge gap, as many patients experience both wet and dry AMD simultaneously, yet little prior research has examined how these therapies interact. - The research team, including collaborators from Associated Retinal Consultants, is preparing the manuscript for submission to Ophthalmology, the flagship journal of the American Academy of Ophthalmology.
- Eflornithine (DFMO), a decades-old drug originally used for West African sleeping sickness, has shown promising results in treating Bachmann-Bupp syndrome (BABS), an ultra-rare genetic disorder affecting only about 20 patients worldwide. - Five BABS patients treated with DFMO through FDA single-patient protocols have demonstrated visible improvements in muscle tone, developmental milestones, and hair growth by targeting the overactive ODC1 enzyme pathway. - A new collaboration between Corewell Health, Michigan State University, and Every Cure aims to accelerate research and navigate regulatory pathways to bring this potential treatment to more patients with the rare genetic condition. - The drug's established safety profile from previous uses provides researchers with dosing guidance and known side effects, offering advantages over developing entirely new medications for this orphan disease.
- Marie Hindee, a 77-year-old patient with chronic lymphocytic leukemia and small lymphocytic lymphoma, achieved remission after receiving CAR T-cell therapy at Corewell Health Beaumont Hospital in Royal Oak. - The FDA-approved liso-cel CAR T-cell therapy, which modifies patient T-cells to target cancer cells, offers high remission rates and potentially durable results with just one treatment. - Hindee became the first chronic lymphocytic leukemia patient to receive this treatment at the facility after 15 years of battling blood cancer through multiple chemotherapy rounds and targeted therapies. - Research is expanding CAR T-cell therapy applications beyond blood cancers to solid tumors including breast, lung, melanoma, and pancreatic cancers with promising early clinical trial results.
- Corewell Health in Michigan and Ochsner MD Anderson in Louisiana have become among the first health systems in their respective states to offer newly FDA-approved tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma patients. - TIL therapy represents a personalized immunotherapy approach that harvests immune cells from a patient's tumor, multiplies them in the laboratory to billions of cells, and reinfuses them to enhance the body's cancer-fighting capabilities. - Clinical trials demonstrate that many patients continue responding five years after TIL treatment, with tumor shrinkage or elimination observed in cases where conventional therapies had failed. - The therapy is specifically indicated for patients with unresectable or metastatic melanoma who have exhausted standard treatment options, providing a new hope for this challenging patient population.
- A 46-year-old patient with adenoid cystic carcinoma became the first in the U.S. to receive step-and-shoot proton arc therapy, experiencing minimal side effects despite the cancer's invasion of nerves leading to her brain. - The groundbreaking radiation technique delivers treatment more precisely and continuously than conventional methods, significantly reducing damage to surrounding healthy tissue and allowing the patient to maintain normal daily activities throughout treatment. - Researchers at Corewell Health are already developing the next generation of this technology, called DynamicARC®, which promises even more precise targeting with no lag time between radiation doses and is expected to receive FDA approval next year.
